Silver Book Fact

Slowing the progression of Parkinson’s disease by just 10% would save $327 million (in direct and indirect costs) to the U.S. annually.

Kurlan R, Clark S, Shoulson I, Penny J. Economic Impact of Protective Therapy for Early Parkinson’s Disease. Ann Neurol. 1988; 24(1): 153

Reference

Title
Economic Impact of Protective Therapy for Early Parkinson’s Disease
Publication
Ann Neurol
Publication Date
1988
Authors
Kurlan R, Clark S, Shoulson I, Penny J
Volume & Issue
Volume 24, Issue 1
Pages
153

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Research breakthroughs that slow the onset and progression of Alzheimer’s disease could achieve annual Medicare savings of $51 billion by 2015, $126 billion by 2025, and $444 billion by 2050.  
  • A large set of NIH clinical trials are assessing interventions (including dietary supplements–creatine and coenzyme Q10) that may slow the progression of Parkinson’s disease.  
  • Galantamine, a cholinesterase inhibitor, delays Alzheimer’s patients’ need for full-time care, with overall cost savings estimated between $323 and $4,256 per patient.  
  • Medicaid Costs, Slowed Progression  
  • Some studies have indicate that the management of high cholesterol, type 2 diabetes, high blood pressure, overweight or obesity, and other cardiovascular risk factors may help avoid or delay cognitive…